期刊
IMMUNITY
卷 43, 期 1, 页码 15-28出版社
CELL PRESS
DOI: 10.1016/j.immuni.2015.07.001
关键词
-
类别
资金
- NIH [U19 AI083019, R01 AI074973, 5T32A100716334]
- Cancer Research Institute
- American Cancer Society
When type III interferon (IFN-lambda; also known as interleukin-28 [IL-28] and IL-29) was discovered in 2003, its antiviral function was expected to be analogous to that of type I IFNs (IFN-alpha and IFN-beta) via the induction of IFN-stimulated genes (ISGs). Although IFN-lambda stimulates expression of antiviral ISGs preferentially in cells of epithelial origin, recent studies have defined additional antiviral mechanisms in other cell types and tissues. Viral infection models using mice lacking IFN-lambda signaling and SNP associations with human disease have expanded our understanding of the contribution of IFN-lambda to the antiviral response at anatomic barriers and the immune response beyond these barriers. In this review, we highlight recent insights into IFN-lambda functions, including its ability to restrict virus spread into the brain and to clear chronic viral infections in the gastrointestinal tract. We also discuss how IFN-lambda modulates innate and adaptive immunity, autoimmunity, and tumor progression and its possible therapeutic applications in human disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据